EDIT vs LIN
Editas Medicine Inc (EDIT) versus Linde plc Ordinary Shares (LIN) — a side-by-side from cached financials, not a winner call.
Editas Medicine Inc (EDIT) is a biotechnology company listed on NASDAQ.
Linde plc Ordinary Shares (LIN) is a specialty chemicals company listed on US.
Latest reported EDIT revenue for 2024-12-31 was $32.3M. Net income was -$237.1M. Revenue was down 58.6% from 2023-12-31 to 2024-12-31. EDIT currently screens at market cap $375.2M.
Latest reported LIN revenue for 2025-12-31 was $33.99B. Net income was $6.90B. Revenue was up 3.0% from 2024-12-31 to 2025-12-31. LIN currently screens at market cap $223.87B and trailing P/E 34.5.
EDIT currently screens at market cap $375.2M. LIN currently screens at market cap $223.87B and trailing P/E 34.5.
Not investment advice. Open the EDIT and LIN stock pages for the full models.
Not investment advice.